GenOne™ Spray
(Gentamicin Sulfate, USP with Betamethasone Valerate, USP)

GenOne is a gentamicin sulfate with betamethasone valerate topical spray that is indicated for the treatment in dogs of infected superficial lesions for bacteria sensitive to gentamicin. Each milliliter contains gentamicin sulfate equivalent to 0.57 mg gentamicin base, and betamethasone valerate equivalent to 0.284 mg betamethasone. Gentamicin, a broad-spectrum antibiotic, is a highly effective topical treatment for bacterial infections of the skin. Betamethasone valerate, a synthetic glucocorticoid, has been shown to provide anti-inflammatory and antipruritic activity in the topical management of corticosteroid-responsive infected superficial lesions in dogs. For topical use in dogs only. Prescription.

<table>
<thead>
<tr>
<th>Product</th>
<th>Item#</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>GenOne Spray</td>
<td>501007</td>
<td>60 mL</td>
</tr>
<tr>
<td></td>
<td>502007</td>
<td>120 mL</td>
</tr>
<tr>
<td></td>
<td>503007</td>
<td>240 mL</td>
</tr>
</tbody>
</table>

Features and benefits

- Broad-spectrum antibiotic that is effective for the treatment of bacterial infections of the skin.
- Betamethasone Valerate, USP provides anti-inflammatory and anti-pruritic activity.
- Spray allows “hands off” treatment.
- Provides rapid relief for bacterial infections and also relieves pain and itching.
- Odorless and colorless to prevent staining.
GenOne™ Spray
(Gentamicin Sulfate, USP with Betamethasone Valerate, USP)

For Topical Use In Dogs Only
For Animal Use Only

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
ANADA #200-415, Approved by FDA

Description: Each mL contains: gentamicin sulfate, USP equivalent to 0.57 mg gentamicin base, betamethasone valerate, USP equivalent to 0.284 mg betamethasone, 163 mg isopropyl alcohol, propylene glycol, methylparaben and propylparaben as preservatives, purified water q.s. Hydrochloric acid may be added to adjust pH.

Chemistry: Gentamicin is a mixture of aminoglycoside antibiotics derived from the fermentation of Micromonospora purpurea. Gentamicin sulfate is a mixture of sulfate salts of the antibiotics produced in this fermentation. The salts are weakly acidic and freely soluble in water. Gentamicin sulfate contains not less than 500 micrograms of gentamicin base per milligram.

Betamethasone valerate is a synthetic glucocorticoid.

Pharmacology: Gentamicin, a broad-spectrum antibiotic, is a highly effective topical treatment for bacterial infections of the skin. In vitro, gentamicin is bactericidal against a wide variety of gram-positive and gram-negative bacteria isolated from domestic animals. Specifically, gentamicin is active against the following organisms isolated from canine skin: Alcaligenes sp., Citrobacter sp., Klebsiella sp., Pseudomonas aeruginosa, indolepositive and negative Proteus sp., Escherichia coli, Enterobacter sp., Staphylococcus sp., and Streptococcus sp.

Betamethasone valerate emerged from intensive research as the most promising of some 50 newly synthesized corticosteroids in the experimental model described by McKenzie, Atkinson, RM.: Topical activities of betamethasone valerate in veterinary medicine has been shown in patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations. If ingestion should occur, patients should be closely observed for the usual signs of adrenocorticoid overdosage that include sodium retention, potassium loss, fluid retention, weight gains, polydipsia, anorexia, polyuria, and diarrhea (occasionally bloody) have been observed in dogs. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Precautions: Antibiotic susceptibility of the pathogenic organism(s) should be determined prior to use of this preparation. Use of topical antibiotics may permit overgrowth of nonsusceptible bacteria, fungi, or yeasts. If this occurs, treatment should be instituted with other appropriate agents as indicated.

Administration of recommended dose beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely.

Avoid ingestion. Oral or parenteral use of corticosteroids, depending on dose, duration, and specific steroid may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations.

Contraindications: If hypersensitivity to any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted.

Dosage and administration: Prior to treatment, remove excessive hair and clean the lesion and adjacent area. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer 2 to 4 times daily for 7 days.

Each depression of the sprayer head delivers 0.7 mL of GenOne™ Spray.

Toxicity: GenOne™ Spray was well tolerated in an abraded skin study in dogs. No treatment-related toxicological changes in the skin were observed. Systemic effects directly related to treatment were confined to histological changes in the adrenals, liver, and kidney and to organ-to-body weight ratios of adrenals. All were dose related, were typical for or not unexpected with corticosteroid therapy, and were considered reversible with cessation of treatment.

Side effects: Side effects such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Administration of recommended dose beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely.

Avoid ingestion. Oral or parenteral use of corticosteroids, depending on dose, duration, and specific steroid may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations.

If ingestion should occur, patients should be closely observed for the usual signs of adrenocorticoid overdosage that include sodium retention, potassium loss, fluid retention, weight gains, polydipsia, and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects.

References:

How supplied: GenOne Spray is available in:
NDC 13985-007-60 60 mL plastic bottle
NDC 13985-007-12 120 mL plastic bottle
NDC 13985-007-24 240 mL plastic bottle

Storage: Store upright between 2° and 30°C (36°F and 86°F).

Rev. 07/22